Evidence map›Paper›PMID 24525690›Full record

Trial reportThe American journal of psychiatry2014

Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.

Henry R Kranzler, Jonathan Covault, Richard Feinn, Stephen Armeli, Howard Tennen, Albert J Arias, Joel Gelernter, Timothy Pond, Cheryl Oncken, Kyle M Kampman

Erratum issuedAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 100 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 4 pooled it
19.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 4 syntheses or guidelines pooled it, 184 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Henry R Kranzler
Jonathan Covault
Richard Feinn
Stephen Armeli
Howard Tennen
Albert J Arias
Joel Gelernter
Timothy Pond
Cheryl Oncken
Kyle M Kampman
University of Connecticut · US

Funding

Vulnerabilities for coping-related drinking among post-college young adultsP60AA003510 · NIAAA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI HESSELBROCK, VICTOR M · 2008 to 2017
$17.5M
WHO COLLABORATIVE PROJECT ON MANAGEMENT OF HARMFUL ALCOHOL CONSUMPTIONP50AA003510 · NIAAA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI KRANZLER, HENRY RICHARD · 1985 to 2007
$13.6M
Novel Approaches to Alcoholism Pharmacotherapy and RiskK24AA013736 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI KRANZLER, HENRY RICHARD · 2002 to 2012
$1.5M
NIAAA NIH HHS K24 AA013736NIAAA NIH HHS K24 AA13736NIAAA NIH HHS P50 AA003510NIAAA NIH HHS P60 AA003510NIAAA NIH HHS P60 AA03510
6 · The paper itself

Abstract

objectiveTopiramate has been shown to reduce drinking and heavy drinking in individuals with alcohol dependence whose goal was to stop drinking. The authors evaluated the efficacy and tolerability of topiramate in heavy drinkers whose treatment goal was to reduce drinking to safe levels.

methodA total of 138 individuals (62.3% men) were randomly assigned to receive 12 weeks of treatment with topiramate (N=67), at a maximal daily dose of 200 mg, or matching placebo (N=71). Both groups received brief counseling to reduce drinking and increase abstinent days. It was hypothesized that topiramate-treated patients would be better able to achieve these goals, and it was predicted that based on prior research, the effects would be moderated by a single nucleotide polymorphism (rs2832407) in GRIK1, encoding the kainate GluK1 receptor subunit.

resultsThe rate of treatment completion was 84.9% and equal by treatment group. Topiramate treatment significantly reduced heavy drinking days and increased abstinent days relative to placebo. Patients receiving topiramate also had lower concentrations of the liver enzyme γ-glutamyl transpeptidase and lower scores on a measure of alcohol-related problems than the placebo group. In a European American subsample (N=122), topiramate's effect on heavy drinking days was significantly greater than that for placebo only in rs2832407 C-allele homozygotes.

conclusionsThese findings support the use of topiramate at a daily dose of 200 mg to reduce heavy drinking in problem drinkers. The moderator effect of rs2832407, if validated, would facilitate the identification of heavy drinkers who are likely to respond well to topiramate treatment and provide an important personalized treatment option. The pharmacogenetic findings also implicate the kainate receptor in the mechanism of topiramate's effects on heavy drinking.

Indexed as

Polymorphism, Single NucleotideAdultAlcoholismDouble-Blind MethodFemaleFructoseHumansKainic Acid ReceptorsMaleMiddle AgedTopiramateTreatment OutcomeFructoseKainic Acid ReceptorsTopiramate

Identifiers

PMID24525690
PMCPMC3997125
OpenAlexW2113673166

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.